Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 356

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 356
---
     |       |     |           |    (117,850 | ) |
| Effect of exchange rate changes                                                              |     |                                               |    (97,961 | )  |     |                  |           — |   |     |             |        — |   |     |       |     |           |     (97,961 | ) |
| Total comprehensive profit                                                                   |     |                                               |   (108,531 | )  |     |                  |    (107,280 | ) |     |             |        — |   |     |       |     |           |    (215,811 | ) |
| Total comprehensive loss                                                                     |     | $                                             | (3,362,955 | )  |     | $                | (12,279,309 | ) |     | $           |  202,577 |   |     |       |     | $         | (15,439,687 | ) |
| Basic and diluted loss per share (in USD)                                                    |     | $                                             |      (0.08 | )  |     | $                |       (0.32 | ) |     |             |        — |   |     |       |     | $         |       (0.42 | ) |
| Weighted average common shares used in computing basic and diluted net loss per common share |     |                                               |  4,193,689 | ** |     |                  |     954,401 | * |     |             |          |   |     |       |     |           |  35,910,102 |   |

____________ *This gives effect to the reverse stock split of 1 -for-40as of September 27, 2024. **On March 21, 2024, Kadimastem conducted a reverse share split at a 10 -for-1ratio. The number of weighted shares (42,424,000) shown on Kadimastem’s audited financial statements on page G -40were presented prior to said share consolidation. The accompanying notes are an integral part of these unaudited pro forma condensed combined financial statements.

196 Kadimastem Ltd. & NLS Pharmaceutics Ltd.
Notes to accompanying Financial Statements 1.Description of the Proposed Transaction and Basis of Presentation NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (“NLS”), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA